Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
- Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
- Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
- MA State Medical License 2008 - 2025
- American Board of Internal Medicine Hematology
Clinical Trials
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2018 Aug 23
Publications & Presentations
PubMed
- Leukemia circulation kinetics revealed through blood exchange method.Alex B Miller, Felicia H Rodriguez, Adam Langenbucher, Lin Lin, Christina Bray, Sarah Duquette, Ye Zhang, Dan Goulet, Michael T Hemann, Scott R Manalis, Andrew A Lane,...> ;Communications Biology. 2024 Apr 20
- Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival.Julia H Keating, Christopher J Fay, Donna S Neuberg, Nicole R LeBoeuf, Shai Shimony, Marlise R Luskin, Andrew A Lane> ;Blood Advances. 2024 Apr 11
- 1 citationsPivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
- Join now to see all
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- Stemline Therapeutics Announces That Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointOctober 31st, 2017
- Link Between down Syndrome, Leukemia UncoveredApril 20th, 2014
- Exposure to Ultraviolet Radiation May Propel Transformation of BPDCN Cells to Leukemia in the SkinJune 14th, 2023
- Join now to see all
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: